Ophthalmic ciprofloxacin
Article Abstract:
Ciprofloxacin is an antibiotic that has been used orally to treat serious infections. It was recently approved for intravenous use, and is now marketed in an ophthalmic formulation for treatment of bacterial keratitis (inflammation of the cornea) and conjunctivitis. A variety of bacteria may cause keratitis or conjunctivitis, for which many ophthalmic antimicrobial treatments are already available. Ciprofloxacin is a type of antibiotic that is active against many bacteria, some of which are resistant to common antibiotics. The drug is recognized for its ability to sterilize a wide assortment of bacterial corneal ulcers, but no rigorous studies have yet been done. Increased incidence of bacterial resistant to this antibiotic, when used orally has been reported. Ophthalmic ciprofloxacin may cause mild stinging and burning, local irritation, redness, pain, and white precipitates have temporarily occurred in the corneas of some patients. The antibiotic is not recommended for children under 12 years old. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1991
User Contributions:
Comment about this article or add new information about this topic:
Gatifloxacin and moxifloxacin: two new fluoroquinolones
Article Abstract:
The FDA has approved the use of gatifloxacin and moxifloxacin for treating pneumonia, bronchitis, and sinusitis. Both drugs belong to a class of antibiotics called fluoroquinolones. Gatifloxacin is sold under the trade name Tequin and moxifloxacin under the trade name Avelox. They are active against Streptococcus pneumoniae, Staphylococcus aureus, enterococci, Legionella, Chlamydia, Mycoplasma pneumoniae, Mycobacterium tuberculosis, Haemophilus influenza, and Neisseria. However, some bacteria that have become resistant to vancomycin and methicillin may be resistant to these drugs also.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar)
Article Abstract:
Moxifloxacin 0.5% (Vigamox) and gatifloxacin 0.3% (Zymar) are two new fluoroquinolone solutions use in ophthalmic treatment of bacterial conjunctivitis. The clinical studies found that moxifloxacin 0.5% was 93%effective and gatifloxacin 0.3% was 77% effective on people suffering from culture positive bacterial conjunctivitis.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. SARS -- one year later
- Abstracts: The potential rewards of multigenerational vacations are many. An unforgettable road trip
- Abstracts: Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes
- Abstracts: Hemodynamic effects of sildenafil in men with severe coronary artery disease. Prevention of Cardiovascular events after Percutaneous Coronary Intervention
- Abstracts: 2047Case 14-2006: A 25-year-old woman with anemia and iron overload. Case 19-2004: a 12-year-old boy with fatigue and eosinophilia